{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:07:24Z","timestamp":1790888844274,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102605","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:09:31Z","timestamp":1782079771000},"page":"102605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?"],"prefix":"10.1016","volume":"24","author":[{"given":"Fabien","family":"Moinard-Butot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-727X","authenticated-orcid":false,"given":"Simon","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-1554","authenticated-orcid":false,"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0001","doi-asserted-by":"crossref","first-page":"829\u201141","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102605_bib0002","doi-asserted-by":"crossref","first-page":"1277\u201190","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clgc.2026.102605_bib0003","doi-asserted-by":"crossref","first-page":"1289\u2011300","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102605_bib0004","doi-asserted-by":"crossref","first-page":"1116\u201127","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102605_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.01.007","article-title":"Towards a consensus on the management of metastatic renal cell carcinoma: insights from a European Delphi study","author":"Albiges","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102605_bib0006","article-title":"Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102605_bib0007","first-page":"331\u20118","article-title":"Cost effectiveness of treatment sequences in advanced renal cell carcinoma","volume":"6","author":"Mason","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102605_bib0008","doi-asserted-by":"crossref","first-page":"1729\u201139","DOI":"10.2147\/PPA.S460994","article-title":"Treatment preferences among patients with renal cell carcinoma: results from a discrete choice experiment","volume":"18","author":"Ornstein","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"10.1016\/j.clgc.2026.102605_bib0009","doi-asserted-by":"crossref","first-page":"357\u201171","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0010","doi-asserted-by":"crossref","first-page":"987\u201197","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0011","doi-asserted-by":"crossref","first-page":"604\u201113","DOI":"10.1002\/psp4.12210","article-title":"Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with Sunitinib-treated cancer","volume":"6","author":"Diekstra","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102605_bib0012","doi-asserted-by":"crossref","first-page":"2002\u20118","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102605_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309778","article-title":"Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): results from cohort B of an open-label, phase 1 study","volume":"19","author":"Cohen","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0014","doi-asserted-by":"crossref","first-page":"1307\u201126","DOI":"10.2217\/fon.15.52","article-title":"Nivolumab: targeting PD-1 to bolster antitumor immunity","volume":"11","author":"Brahmer","year":"2015","journal-title":"Fut Oncol"},{"key":"10.1016\/j.clgc.2026.102605_bib0015","doi-asserted-by":"crossref","unstructured":"Shchelokov D., Demin Jr O. Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study. MAbs. 15(1):2156317. doi:10.1080\/19420862.2022.2156317. .","DOI":"10.1080\/19420862.2022.2156317"},{"issue":"11","key":"10.1016\/j.clgc.2026.102605_bib0016","doi-asserted-by":"crossref","first-page":"1026\u201138","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102605_bib0017","doi-asserted-by":"crossref","first-page":"1370\u201185","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102605_bib0018","doi-asserted-by":"crossref","first-page":"21\u20119","DOI":"10.1016\/j.ejca.2022.11.013","article-title":"Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status","volume":"180","author":"Carril-Ajuria","year":"2023","journal-title":"Eur J Cancer"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2026.102605_bib0019","first-page":"363\u2011363","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial","volume":"42","author":"Tannir","year":"2024","journal-title":"JCOr"},{"issue":"4","key":"10.1016\/j.clgc.2026.102605_bib0020","doi-asserted-by":"crossref","first-page":"628\u201134","DOI":"10.1016\/j.eururo.2017.07.041","article-title":"Cost effectiveness of Nivolumab in advanced renal cell carcinoma","volume":"73","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102605_bib0021","first-page":"808\u201118","article-title":"Meta-analysis of quality of life in cancer patients treated with immune checkpoint inhibitors","volume":"114","author":"Gonzalez","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.clgc.2026.102605_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.clgc.2026.102605_bib0023","doi-asserted-by":"crossref","first-page":"1430\u20117","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102605_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.clgc.2026.102605_bib0025","doi-asserted-by":"crossref","first-page":"1252\u201165","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102605_bib0026","doi-asserted-by":"crossref","first-page":"213\u201127","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102605_bib0027","doi-asserted-by":"crossref","first-page":"883\u201192","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102605_bib0028","doi-asserted-by":"crossref","first-page":"4533\u20114533","DOI":"10.1200\/JCO.2023.41.16_suppl.4533","article-title":"Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"JCO"},{"issue":"36","key":"10.1016\/j.clgc.2026.102605_bib0029","doi-asserted-by":"crossref","first-page":"4240\u20118","DOI":"10.1200\/JCO.20.02295","article-title":"Optimized management of Nivolumab and Ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clgc.2026.102605_bib0030","doi-asserted-by":"crossref","first-page":"6687\u201195","DOI":"10.1158\/1078-0432.CCR-21-2283","article-title":"Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial","volume":"27","author":"Regan","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clgc.2026.102605_bib0031","doi-asserted-by":"crossref","first-page":"2085\u201197","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2026.102605_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003473","article-title":"Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Tzeng","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2026.102605_bib0033","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS366","article-title":"PDIGREE: an adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)","volume":"39","author":"Zhang","year":"2021","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.clgc.2026.102605_bib0034","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12885-023-10881-8","article-title":"A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study","volume":"23","author":"Gravis","year":"2023","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.clgc.2026.102605_bib0035","doi-asserted-by":"crossref","first-page":"2913\u201123","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of Nivolumab and Salvage Nivolumab\/Ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0036","first-page":"1020\u20118","article-title":"Open-label, single-arm phase II study of Pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102605_bib0037","doi-asserted-by":"crossref","first-page":"612\u201124","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102605_bib0038","doi-asserted-by":"crossref","first-page":"952\u20118","DOI":"10.1016\/j.eururo.2014.12.036","article-title":"Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma","volume":"67","author":"Gr\u00fcnwald","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102605_bib0039","first-page":"577\u201184","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2026.102605_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS402","article-title":"SWOG S1931 (PROBE): phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.clgc.2026.102605_bib0041","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","article-title":"Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial","volume":"24","author":"Iisager","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2026.102605_bib0042","unstructured":"Institut Paoli-Calmettes. Post-immunotherapy nephrectomy for metastatic kidney cancer after complete or major response to systemic therapy [Clinical trial registration] [Internet]. clinicaltrials.gov; mars 2025 Clinical trial registration NCT06882486. Disponible sur: https:\/\/clinicaltrials.gov\/study\/NCT06882486"},{"issue":"8","key":"10.1016\/j.clgc.2026.102605_bib0043","doi-asserted-by":"crossref","first-page":"1061\u20116","DOI":"10.1007\/s00345-016-1865-8","article-title":"Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome","volume":"34","author":"Brehmer","year":"2016","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102605_bib0044","doi-asserted-by":"crossref","first-page":"456\u201160","DOI":"10.1111\/j.1464-410X.2009.08490.x","article-title":"Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma","volume":"104","author":"Daliani","year":"2009","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.clgc.2026.102605_bib0045","first-page":"141\u20119","article-title":"Surgical metastasectomy in renal cell carcinoma: a systematic review","volume":"2","author":"Ouzaid","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102605_bib0046","doi-asserted-by":"crossref","first-page":"44\u20119","DOI":"10.1016\/j.juro.2016.07.079","article-title":"Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"197","author":"Zaid","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102605_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102134","article-title":"Effect of treatment of residual disease after immunotherapy-based combinations on complete response rate of patients with metastatic renal cell carcinomas","volume":"22","author":"Moinard-Butot","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102605_bib0048","doi-asserted-by":"crossref","first-page":"364\u201172","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102605_bib0049","doi-asserted-by":"crossref","first-page":"171\u20118","DOI":"10.1159\/000527287","article-title":"Treatment outcomes of stereotactic body radiotherapy in patients with synchronous and metachronous oligometastatic renal cell carcinoma","volume":"107","author":"Guler","year":"2023","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102605_bib0050","first-page":"437\u201146","article-title":"Survival by depth of response and efficacy by International metastatic renal cell carcinoma database Consortium subgroup with Lenvatinib plus Pembrolizumab versus Sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2026.102605_bib0051","doi-asserted-by":"crossref","first-page":"3277\u201182","DOI":"10.1002\/cncr.26666","article-title":"Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome","volume":"118","author":"Sadeghi","year":"2012","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.clgc.2026.102605_bib0052","doi-asserted-by":"crossref","first-page":"1606\u201110","DOI":"10.1001\/jamaoncol.2020.2169","article-title":"Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma","volume":"6","author":"Ravi","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2026.102605_bib0053","doi-asserted-by":"crossref","first-page":"508\u2011508","DOI":"10.1200\/JCO.2026.44.7_suppl.508","article-title":"Characterization of depth and durability of response in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) who received cabozantinib plus nivolumab (C+N): long-term follow-up and exploratory analysis of CheckMate 9ER","volume":"44","author":"Su\u00e1rez","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102605_bib0054","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97365-6","article-title":"The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database","volume":"11","author":"Wei","year":"2021","journal-title":"Sci Rep"},{"issue":"43","key":"10.1016\/j.clgc.2026.102605_bib0055","article-title":"State of the art: multidisciplinary management of oligometastatic renal cell carcinoma","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102605_bib0056","doi-asserted-by":"crossref","first-page":"1883\u20119","DOI":"10.1586\/era.10.195","article-title":"Long-term management of patients with metastatic renal cell carcinoma on targeted agents","volume":"10","author":"Jonasch","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"issue":"25","key":"10.1016\/j.clgc.2026.102605_bib0057","doi-asserted-by":"crossref","first-page":"2867\u201170","DOI":"10.1200\/JCO.22.00834","article-title":"Up-front Nivolumab with or without salvage Ipilimumab across international metastatic database consortium risk groups in metastatic clear cell renal cell carcinoma","volume":"40","author":"Voss","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102605_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960751","article-title":"Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: a real-world, single-centre experience","volume":"12","author":"Bimbatti","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102605_bib0059","doi-asserted-by":"crossref","first-page":"1931\u20119","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"Verhoeff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102605_bib0060","article-title":"Ultrasensitive circulating tumor DNA pilot study distinguishes complete response and partial response with immunotherapy in patients with metastatic renal cell carcinoma","volume":"7","author":"Chehrazi-Raffle","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102605_bib0061","doi-asserted-by":"crossref","first-page":"1289\u201199","DOI":"10.1016\/S1470-2045(25)00380-8","article-title":"Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial","volume":"26","author":"Tang","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:58:35Z","timestamp":1783738715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326001059"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102605","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102605"}}